

Stephen Booth BChir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8467547/publications.pdf>

Version: 2024-02-01

24
papers

1,377
citations

932766

10
h-index

794141

19
g-index

25
all docs

25
docs citations

25
times ranked

2968
citing authors

#	ARTICLE	IF	CITATIONS
1	Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy. <i>British Journal of Haematology</i> , 2022, 196, 892-901.	1.2	23
2	Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19. <i>JAMA Network Open</i> , 2022, 5, e220130.	2.8	34
3	Bone health and glucocorticoid-containing lymphoma therapy – a review of risk factors and preventative measures. <i>British Journal of Haematology</i> , 2022, 198, 431-442.	1.2	6
4	Risk of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination prior to the recognition of vaccine-induced thrombocytopenia and thrombosis: A self-controlled case series study in England. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12698.	1.0	8
5	Platelet transfusion and anticoagulation in hematological cancer-associated thrombosis and thrombocytopenia: The CAVEaT multicenter prospective cohort. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1830-1838.	1.9	4
6	Epigenetic targeting in lymphoma. <i>British Journal of Haematology</i> , 2021, 192, 50-61.	1.2	4
7	Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP. <i>Blood Advances</i> , 2021, 5, 2229-2236.	2.5	14
8	A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma. <i>BMC Cancer</i> , 2021, 21, 851.	1.1	2
9	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
10	The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2021, 192, 1035-1038.	1.2	10
11	Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0
12	Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. <i>Blood</i> , 2020, 136, 2881-2892.	0.6	479
13	Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4337-4346.	2.5	11
14	COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 1309-1316.	5.1	473
15	Antiphospholipid syndrome and challenges with direct oral anticoagulants. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2020, 81, 1-11.	0.2	2
16	Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy. <i>European Journal of Haematology</i> , 2020, 105, 476-483.	1.1	26
17	Outcomes of Adult and Pediatric Patients with Hematologic Malignancies and COVID-19: A Systematic Review and Meta-Analysis of 1847 Patients. <i>Blood</i> , 2020, 136, 39-41.	0.6	0
18	Standard-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. <i>British Journal of Haematology</i> , 2019, 187, 185-194.	1.2	49

#	ARTICLE	IF	CITATIONS
19	Efficacy of Râ€CVP in patients with late relapse of diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2019, 186, e191-e195.	1.2	0
20	Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly <scp>DLBCL</scp> patients treated with Râ€<scp>CHOP</scp>. British Journal of Haematology, 2019, 186, e94-e98.	1.2	10
21	Impact of intended and relative dose intensity of Râ€CHOP in a large, consecutive cohort of elderly diffuse large Bâ€cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age. Journal of Internal Medicine, 2019, 285, 681-692.	2.7	31
22	Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious. Blood, 2019, 134, 1564-1564.	0.6	2
23	Risk of Fracture Following Front Line R-CHOP Immunochemotherapy in Older Patients with Diffuse Large B Cell Lymphoma Is Common. Blood, 2019, 134, 1615-1615.	0.6	0
24	CNS Relapse Risk in Consecutive R-CHOP/R-Mini-CHOP-Treated Elderly DLBCL Is Low, with High Risk Particularly Apparent in Those with CNS IPI 5-6 and/or Renal/Adrenal Involvement. Blood, 2018, 132, 1694-1694.	0.6	0